Achondroplasia is a clinical condition defined by shorter stature and 19 disproportionate limb length. Force production in able-bodied individuals (controls) 20 is proportional to muscle size, but given the disproportionate nature of 21 Achondroplasia, normalising to anatomical cross sectional area (ACSA) is 22
inappropriate. The aim of this study was to assess specific force of the vastus 23 lateralis (VL) in 10 adults with Achondroplasia (22 3 yrs) and 18 gender matched 24
controls (22 2 yrs). Isometric torque (iMVC) of the dominant knee extensors (KE) 25
and in vivo measures of VL muscle architecture, volume, activation and patella 26 tendon moment arm were used to calculate VL physiological CSA (PCSA), fascicle 27 force and specific force in both groups. Achondroplasia muscle volume was 53% 28 smaller than controls (284 36 vs 604 102 cm 3 , P < 0.001). KE iMVC was 63% lower 29
in Achondroplasia compared to controls (95 24 vs 256 47 Nm, P < 0.001). 30
Activation and moment arm length were similar between groups (P > 0.05), but 31 coactivation of Achondroplasia bicep femoris was 70% more than controls (43 20 vs 32 13 5 %, P < 0.001). Achondroplasia had 58% less PCSA (43 10 vs 74.7 14 cm 2 , P < 33 0.001), 29% lower fascicle force (702 235 vs 1704 303 N, P < 0.001) and 29% lower 34 specific force than controls (17 6 vs 24 6 Ncm -2
Introduction
Achondroplasia is a condition characterised by disproportionate shorter limb length, 48 to stature, compared to age matched average sized individuals (18, 21, 39, 45) . The 49 contribution of force from the muscle in proportionally smaller groups has been 50 investigated with force production appearing to be proportional to muscle 51 morphology, such as muscle volume and fascicle length (23, 37). With 52 Achondroplasia displaying disproportionate limb length and reduced whole body and 53 segmental muscle mass, the muscle architecture and force production capacity may 54 in turn be altered, but such observations have not been identified in Achondroplasic 55
populations. 56 57
Muscle morphology, defined here as muscle size and architecture, is a primary 58 determinant of muscle function and can account for some of the differences 59 observed in proportionally smaller people (6, 23, 24, 37, 43, 44, 49) . Primarily, the 60 determinants of muscle force are: muscle shortening velocity, physiological cross 61 sectional area (PCSA) of the muscle, fascicle length and muscle volume, respectively 62 (38). Neural factors of the agonists and antagonists also contribute to force 63 production as well as the biomechanical form of the joint (29, 32, 34) . In numerous 64
clinical conditions, such as the aging and cerebral palsy, the prevalence of weakness 65 corresponds with functional impairments such as slower walking speeds and 66 reduced performance of functional tasks (10, 22) . In children with Achondroplasia 67 isometric knee extension strength is less than age matched controls (51); there is 68 however no comparison of force production capacity in adults with Achondroplasia, 69 nor is there any measure of strength normalised for differences in muscle 70 morphology or size. 71 (52). Furthermore, recently, a large cohort of adult males was measured in the VL, 79 which can be used as a reference data set (50). To the Authors knowledge there has 80 been no measurement of force production in Achondroplasic populations. 81
Furthermore, to the authors knowledge, there appears to be no information on the 82 adult Achondroplasic population in relation to force production, other than a general 83 assumption that muscle mass is lower in this group compared to age matched 84 average sized people, hereafter referred to as 'controls'. The measurement of 85 specific force therefore, will allow a comparison between Achondroplasia and 86 controls that may differ in terms of neuromuscular, biomechanical and architectural 87
properties of the myotendinous unit 88
89
The aim of this study therefore is to assess specific force in adult males with 90 Achondroplasia, and to identify the neural, morphological and biomechanical 91 determinants of any difference in muscle force production between Achondroplasia 92 and controls. 93
94

Methods
95
Participants 96
After written consent, 28 participants volunteered to participate in the study. All 97 were free from any lower limb injury six months prior six to data collection and self-98 reported good health using a physical activity readiness questionnaire (mean (SD): 99 10 adult male Achondroplasia, age: 22 (3) yrs, mass: 61.8 (8.5) kg, stature: 1.38 100 (0.05) m, body fat: 29.3 (2.9) % and 18 adult males, age: 22 (2) yrs, mass: 78.3 (10.7) 101 kg, stature: 1.79 (0.08) m, body fat: 22.4 (5.3) %). Ethical approval was attained by 102 today body fat (%). A default whole body scan (EF 8.4 lSv) was selected for all trials; 111 scans emitted dual energy (140/100 kVp) fan-beam x-rays and lasted for ~7 minutes 112 with each participant being exposed to ~8.4 Sv (5). The scanning region was 195 cm x 65 cm with 1.3 cm line spacing and a 0.2 cm point resolution. 114
115
Specific Force Calculation 116
Strength measurements 117
The torque derived from isometric maximal voluntary contraction (iMVC) of the 118 dominant KE (Achondroplasia n = 9 right leg, control n = 16 right leg) were recorded 119 using an isokinetic dynamometer (Cybex Norm, Cybex International Inc., NY, USA). 120
Participants were seated upright with the dynamometer and chair positioned in 121 accordance with the calibration guidelines given by the manufacturer so the lateral 122 epicondyle was aligned with the dynamometer's central axis of rotation. Particularly 123 in the Achondroplasia group, the chair and dynamometer were adjusted to align the 124 lateral epicondyle if needed; additional padding was placed behind the spine to help 125 maintain a static knee angle throughout contractions. The participants' dominant leg 126 was secured with Velcro straps to the chair on the distal portion of the thigh and to 127 the dynamometer around the lower portion of the tibia (~80% tibia length), 128 according to participant comfort. All participants warmed up by performing six 129 continuous submaximal concentric contractions (60˚·s -1 ) of the KE and knee flexors 130 (KF). Participants then completed a randomised trial of KE iMVCs at 10° degree 131 intervals, between 60° and 100°, to anatomical zero (where 180° was anatomical 132 zero). Due to the chair being repositioned in the Achondroplasia group, joint angles 133 were confirmed and recorded using a manual goniometer. Each participant received 134 ~120 seconds rest between each trial. Throughout iMVC trials, participants were 135 verbally encouraged to exert as much force as possible. Visual feedback was also 136 provided to all participants on a monitor. KE and KF iMVC values were recorded 137 (2000 Hz) on a computer (Macintosh, iMac, Apple Computer, Cupertino, California) 138 via an A/D converter using an acquisition system (AcqKnowledge, Biopac Systems,
142
Agonist Activation 143
Agonist activation of during KE iMVC production is assessed to observed maximal 144 activation of the muscle and is done so while participants are positioned in the 145 isokinetic dynamometer. Firstly, a counter weight was fixed to the dynamometer to 146 minimise the compliance of the device. To measure agonist activation, two rubber 147 stimulation pads (size ranging from 70x90 to 180x100 mm; Uni-Patch, MN, USA) 148
were placed proximally and distally along the transverse plane of the dominant 149 femur. While in a relaxed state, a percutaneous electrical doublet stimulus (DS7, 150
Digitimer stimulator, Welwyn, Garden City, UK) was passed through the KE at 151 increased increments (~50 mV) and regular intervals (~20 seconds) until a plateau of 152 twitch torque was measured. This supramaximal doublet stimulus was applied to the 153 participants KE (inter-stimulus gap 10 µs and pulse width 50 µs) during KE iMVC. 154 Doublet stimulus has been shown to improve the signal-noise ratio in the 155 assessment of central activation (4, 27) . A second doublet was applied 156 approximately 5 seconds after the first stimulus when the muscles were fully 157 relaxed, termed the potentiated doublet. Agonist activation was calculated using the 158
Where; t is the interpolated doublet amplitude of the twitch torque, iMVC is the 162 isometric maximal voluntary contraction torque and T is the potentiated doublet 163 amplitude (3). 164
165
Measurement of Coactivation 166
Co-activation of the KF was measured in all participants during a KE iMVC, and 167 subsequent KF iMVC produced at the angle at which peak KE iMVC was measured. 168
In order to determine coactivation of the KF, surface EMG was recorded over the 169 biceps femoris (BF) as it is the largest of the KF group, and is representative of the KF 170 group as a whole (26). Furthermore, surface EMG was deemed adequate despite theadiposity levels in Achondroplasia (17, 21, 42) , as no differences in EMG readings are 172 observed between groups of differing adiposity (8). Boundaries of the BF were 173 determined using ultrasonography (Technos MXP Biosound Esaote) to ensure 174 consistent placement of EMG electrodes over the KF. When established two pre-175 gelled, unipolar, 10mm, Ag-AgCl percutaneous electromyography (EMG) electrodes 176 (Ambu Neuroline 720, Baltorpbakken, Denmark) were placed distally at ~1/3 of 177 muscle length, to avoid the motor unit of the BF, and ~2mm apart along the mid-178 sagittal plane of the muscle (NORAXON, Arizona, USA). A third electrode was placed 179 on the lateral epicondyle of the same femur as a reference. Prior to the placement of 180 the electrodes, areas of the skin were shaved, then cleaned using an alcoholic wipe 181 to minimise skin impedance and hence improve the EMG signal. Raw EMG data were 182 recorded at 2000 Hz, with a high and low band-pass filter set at 10 and 500 Hz 183 respectively, and a notch set at 50 Hz. The measurement of agonist and antagonist muscle activation are required for the 195 accurate quantification of net KE iMVC production, both of which are used in the 196 calculation of specific force (30, 50). Therefore, net KE iMVC was given as the sum 197 of KE iMVC and KF while a ratio of KF iMVC and KE iMVC was calculated to 198 describe a balance of quadriceps to hamstring strength. between the origin and insertion points with the 50 % percentile marked on the skin. 206
A wire mesh was secured to the skin using non-allergic tape along the transverse 207 plane. The wires were separated ~3 cm apart and ran sagittal to the muscle to act as 208 echo absorbing markers that projected a shadow on the ultrasound image to act as 209 reference points for analysis (48). The 5cm 7.5 MHz linear array probe was placed 210 transversely to the VL with ultrasound transmission gel across the skin. While the 211 probe moved from the medial to the lateral border of the VL, an audio video 212 interleave (AVI) recording with a sampling frequency of 25 Hz (Adobe Premiere 213
Elements version 10, Adobe Systems) was taken. The field of view was set so that 214 anatomical references (femur and aponeurosis between VL and vastus intermedius) 215 were visible at all times. Measurements were taken while the participant was supine 216 and at rest. Individual images (between 5-9), with at least two wire references, were 217 extracted from the recording and used to re-construct the muscle by overlapping the 218 wire and aforementioned anatomical references, on photo editing software (Gimp, 219 transmission gel the probe was held against, and at a perpendicular angle to, the 232 skin with minimal pressure. The depth of view was set to ensure a number of 233 fasciculi insertion points and deep aponeurosis were in view (30). Ultrasound 234 imaging and torque production were synchronised using an external square wave 235 voltage trigger enabling the accurate attainment of iMVC-to-ultrasound. Image 236 recordings were AVI format at a sample frequency of 25 Hz; single images were 237 selected using capture software (Adobe Premiere Elements version 10, Adobe 238 Systems). Images of the VL at rest and iMVC were analysed using digitising software 239 (NIH ImageJ, Version 1.44o, National Institutes of Health, Bethesda, Maryland) 240 whereby fascicle length was determined as the length between the superficial and 241 deep aponeuroses (38) and pennation angle was defined as the insertion angle of 242 the fascicle into the deep aponeurosis (30). With the VL being one of the larger 243 muscles in the body, invariably the dimensions of the probe was not large enough to 244 capture a full fascicle, for these cases linear extrapolation was used to determine 245 fascicle length as little error (2-7%) is observed at the midpoint of the muscle (14, 246 15), again using digitising software described above. 247 248
Physiological Cross Sectional Area 249
The PCSA (cm 2 ) was estimated as the ratio of VL muscle volume to fascicle length 250 (30), assuming the model used to calculate muscle volume is cylindrical and that the 251 muscle fibres are constant length (48). 252 253
Moment arm length 254
A dual-energy X-ray absorptiometry (DEXA) scanning (Hologic Discovery, Vertec 255 Scientific Ltd, UK), in single energy mode (100 kVp), was used to obtain moment arm 256 length of the patella tendon (PT MA ) (12). Participants were asked to lie on their side 257 in a relaxed state. The dominant knee was positioned at the angle acquired from 258 optimal peak force production using a manual goniometer. A single array sagittal 259 plane scan was taken of the knee using a 22.3 x 13.7 cm field of view. To estimate VL fascicle force and in turn specific force the following steps were used: 267 Patella tendon force (N) was calculated using the following equation (41) Tables 1 and 2 ) was performed. Study power was 292 assessed using G*Power and was found to be above 0.8 and alpha was set at ≤ 0.05. 293
All results are reported as means (SD). 294
Results
296
Achondroplasia were 23% smaller in stature (P < 0.001) and 19% lighter in body mass 297 (P < 0.001). There was no difference in age between groups (P = 0.487). 298
299
KE and KF iMVC 300
Adult males with Achondroplasia produced 63% less KE iMVC than controls ( Table  301 1). KF iMVC was also significantly different (Table 1) , again with Achondroplasia 302 producing 82% less KE iMVC than controls. When expressed as a ratio between 303 absolute KE iMVC and KF iMVC, Achondroplasia produced 49% more iMVC from 304 the KE compared to KF than controls (Table 2) . 305 306
Activation and Coactivation 307
There was no difference in maximal activation between Achondroplasia and control 308 participants, however Achondroplasia had a 70% greater coactivation of the BF 309 during KE iMVC compared to controls (Table 1) . 310 311
Net KE iMVC 312
Paired samples t-test revealed that both groups significantly increased KE iMVC 313 when corrected for BF coactivation, with Achondroplasia increasing by 7% and 314 controls by 5% respectively (Table 1 ). The net KE iMVC produced by the VL was 63% 315 less in Achondroplasia compared to controls (Table 1 ). There was no significant 316 correlation between body fat percentage and net KE iMVC in Achondroplasia (r = 317 0.110, P = 0.763) or controls (r = 0.411, P = 0.090). 318 control (Table 1, Figure 2 ) and in turn a 53% smaller muscle volume than controls 323 (Table 1) . Achondroplasia exhibited a 17% greater pennation angle (Table 1) Achondroplasia (R 2 = 0.056, P = 0.508, Figure 1) , whereas for the same variables in 328 controls, a significant relationship did exist (R 2 = 0.286, P = 0.022, Figure 1) . Despite 329 the diverging regression lines, a Z-transformation showed the slopes were similar (P 330 = 0.442). 331
332
Presenting KE iMVC as a ratio to ACSA, Achondroplasia produce 53% less force per 333 unit area compared to controls (Table 2) . When net KE iMVC is expressed as a ratio 334 with total body mass, Achondroplasia again display a 43% reduction to controls 335 (Table 2) . Achondroplasia displayed a 67%, reduction in net KE iMVC when 336 presented as a ratio to LBM (Table 2 ). There was no relationship between ACSA and 337 PCSA (R 2 = 0.016, P > 0.05) for Achondroplasia, whereas a significant relationship for 338 the same variables was observed for controls (R 2 = 0.254, P = 0.032). 339
340
Force Measurements 341
The length of the PT MA were similar between Achondroplasia and controls (Table 1) . 342
All force measurements were statistically lower in Achondroplasia compared to 343 controls with patella tendon force, fascicle force and specific force being 60, 59 and 344 29% lower, respectively (Table 1) . 345
346
Discussion 347
Here we aimed to assess the in vivo muscle morphology, KE iMVC production and 348 specific force of the VL in adults with Achondroplasia and age and gender-matched 349 healthy adults. The main findings were 1) net KE iMVC, VL ACSA, volume and PCSA 350 were smaller in Achondroplasia than controls, 2) differences in net KE iMVC were 351 not accounted for by the differences in muscle size 3) KF coactivation was higher inand biomechanical differences were accounted for, a 29% smaller specific force was 354 observed in Achondroplasia. 355
A large portion of neuromuscular function research describes the relationship 357
between muscle size and force production, suggesting that muscle size is the 358 predetermining factor for muscle strength (7, 33, 50, 54) . Groups of shorter statures 359 consistently present with smaller muscle size and lower MVC strength than their 360 taller counterparts (6, 23, 37, 43, 49) ; when iMVC is normalised to muscle size, 361 differences between control and short stature groups are nullified (6, 23, 49). The 362 data from the present study is partially consistent with these previous findings. 363
Achondroplasia were 82% weaker than controls in terms of KE iMVC, however this 364 was not entirely accounted for by ACSA which was only 20% smaller. It is likely 365 therefore that architectural and neurological factors contribute to weakness in 366 Achondroplasia. It should be noted however that despite accounting for these 367 factors, a deficit in Achondroplasic specific force remains, which could be 368 subsequently attributed to physiological factors between groups or methodological 369 measures of specific force, as discussed below. 370
371
Muscle Morphology in Achondroplasia 372
The extent of group differences in muscle size between Achondroplasia and controls 373 was not consistent for each variable. For example, a 20% smaller VL ACSA in 374 Achondroplasia underestimated the difference in PCSA which was 42% smaller than 375 controls. This was due to the smaller muscle length and hence smaller VL volume in 376 Achondroplasia compared to controls. ACSA must therefore be considered an 377 inaccurate method of assessing contractile area between groups of heterogeneous 378 muscle length such as presented here. 379
380
Although PCSA is the closest approximation to sarcomeres in parallel and therefore 381 contractile area (28), it is possible that PCSA may be overestimated in the 382 Achondroplasic group. The over estimation of PCSA in Achondroplasia is likely due to 383 the differences in architectural properties at iMVC between groups. In controls,muscle architecture at iMVC, with increased pennation angle, fibre shortening and a 386 leftward shift in the length tension relationship observed (30, 46, 47) . Here, only 387 increased pennation angle between groups was observed as resting fibre length not 388 measured. Assuming the Achondroplasic patella tendon is more compliant than 389 controls, given the observations made here, Achondroplasic fibre length is likely to 390 be shorter at iMVC than it would be were patella tendon compliance the same 391 between groups. PCSA is therefore overestimated as PCSA = ACSA/fibre length. 392
Given that PCSA is the denominator when calculating specific force, a large PCSA 393 (with the same fascicle force) equates to a lower specific force. For example, in the 394 present study, Achondroplasia fibre length was 17% shorter and were 17% more 395 pennate at iMVC than controls. Were the fibre angle to remain the same between 396 groups at KE iMVC, fibre length of Achondroplasia would be 9% longer than the 397 presented values and result in a 47% smaller PCSA compared to controls, 5% more 398 than the measured values. This consequently leads to a 15% smaller Achondroplasic 399 specific force compared to controls. The differences in muscle architecture at iMVC 400 between groups therefore appears to contribute to the difference in specific force 401 and could be partly due to a more compliant Achondroplasia patella tendon. 402
However, there appears to be no measure of Achondroplasic tendon compliance 403 within the literature to confirm this. Furthermore, this theory may only explain some 404 of the 23% difference in specific force between groups. 405 406
Specific Force 407
Specific force provides an accurate representation of the in vivo contractile 408 properties of the whole muscle and has been used to described the force 409 characteristics of numerous different cohorts and muscle groups (9, 11, 15, 30, 36-410 38, 43, 50) . Recently it has been shown that inter-individual variability in the 411 measurements of specific force eludes to the fact that population variance in specific 412 force may be due to a lower fibre specific force (i.e. myofilament differences), or an 413 overestimation of muscle area through the inclusion of non-contractile material in 414 the measurement of muscle mass (50). Several research groups have investigated 415 specific force production at the myofilament level to identify intramuscularfascicle level, with no apparent measure of force production made at the 418 myofilament level in Achondroplasia. It could be suggested though, that as 419
Achondroplasia is determined by a collagenous defect during development (19, 20) , 420 the protein structures at the myofilament level may be different to controls, which 421 may contribute to the presented lower Achondroplasic specific force. 422
423
It is possible that the presentation of a lower specific force could be due, in part, to 424 an overestimation of muscle size owing to the use of ultrasound to measure ACSA. 425
Ultrasound, as with MRI, requires the measurement of the area encapsulated by 426 aponeuroses to determine ACSA. The area within these limits includes muscle, 427 connective tissue and fat infiltration. Previous reports (16, 17, 42) and here, show 428 that Achondroplasic individuals have increased body fat percentage. The fibroblast 429 mutation that causes Achondroplasia may also play some part in connective tissue 430 distribution within the muscle, although this is at present unreported. Therefore, the 431 measured Achondroplasic ACSA may reflect a "pseudo-hypertrophy" due to the 432 probable increase of intramuscular fat infiltration, as observed in people with 433 increased body fat (53). This pseudo-hypertrophy would increase muscle volume and 434 PCSA measurement, with no change in contractile mass and in turn reduce the 435 calculation of Achondroplasic specific force; it is important to note here that this 436 methodological limitation is not only present in Achondroplasia. Regardless of these 437 methodological discrepancies, when scaling strength and muscle size, a lower 438 specific force persists in the present Achondroplasia participants which could be 439 attributed to either an infiltration of non-contractile material, differences in single 440 fibre properties or differences in tendon properties. 441
In this study, the use of DEXA to measure PT MA led to two important observations of 444 the Achondroplasic knee. Firstly, there appears to be a lower joint congruency 445 between femur and tibia in the Achondroplasic knee (Figure 3 in Achondroplasia would likely reduce tibiofemoral joint stability. In clinical, injuredof the BF is observed during KE (13, 25, 26) . In the present study, Achondroplasia had 450 a 70% increased coactivation of the BF during KE iMVC compared to controls. 451 Therefore, the increased coactivation of Achondroplasic BF during KE iMVC is likely 452 due to the reduced tibiofemoral joint congruency. Furthermore, the increased 453 coactivation of the Achondroplasic BF may act as an injury prevention mechanism. In 454 this case, Achondroplasic hamstrings are activating during KE to reduce the anterior 455 movement of the tibia in relation to the femur. This would protect ligamentous 456 structures in the knee, such as the anterior cruciate ligament. It is probable that this 457 mechanism exists in other Achondroplasic muscle groups and joints as well as the 458 knee. The increased coactivation of hamstrings, and other muscles, may also 459 influence activities of daily living, such as walking economy. There is however, a lack 460 of comparative data expressing the activation profiles of Achondroplasic muscle 461 during contraction to expand on the theories presented. Therefore, the suggestions 462 made from the current findings warrant further work. 463
464
The second observation from DEXA scanning of the Achondroplasic knee was that 465 absolute PT MA between groups was the same, meaning that Achondroplasia have a 466 longer PT MA relative to the femur (here measured as VL length). This finding is 467 different to other shorter statured groups who show a proportionally smaller 468 moment arms compared to taller statured individuals (37). The relatively larger PT MA 469 in Achondroplasia is likely to aid KE torque production, despite the 63% lower net KE 470 iMVC compared to controls. For example, were the PT MA of the current 471 Achondroplasic population to be proportionally smaller to their femur length (i.e. 472 37% shorter), Achondroplasia would have produced 76% less net KE iMVC than 473 controls. Whilst PT MA appears to aid Achondroplasic torque production, PT MA 474 changes during KE (2, 31, 32) which leads to differences in force production (57). In 475 the present study, we measured PT MA at rest and did not account for changes of 476 PT MA during contraction. We assumed that the changes in PT MA during KE iMVC 477 would be similar between groups as it is unreported if Achondroplasic PT MA changes 478 in a similar fashion to control's PT MA during KE. Any change in Achondroplasic PT MA 479 during contraction may further aid or hinder Achondroplasic torque production, butthis is yet to be observed. The presented data from this study appears to be the only 481 data that accounts for Achondroplasic moment arm during contraction in any joint. 482
483
Clinical Implications 484
The present observations of a lower specific force, higher body fat, shorter stature 485 and lower muscle volume in Achondroplasia, could contribute to those with 486 Achondroplasia requiring a greater relative force production to complete activities of 487 daily living compared to controls, such as walking. During walking, the lower muscle 488 volume and higher body mass of Achondroplasic individuals would likely increase the 489 required force production per step to maintain locomotion. This increased force 490 production may in turn increase Achondroplasic walking economy. Furthermore, the 491 decrease in Achondroplasic KE and KF iMVC, higher hamstring coactivation and 492 lower specific force would suggest Achondroplasia may be at greater risk of falls and 493 reduced postural stability compared to controls, as observed in control groups (40) . 494 Therefore, addressing interventions which aim to increase the absolute force 495 production of Achondroplasic muscle would likely increase their quality of life by 496 aiding walking economy, reducing the risk of falling and reducing injury risk. 497
498
Conclusion 499
This is the first study, to the authors knowledge, that has systematically accounted 500 for various physiological and biomechanical modulators of force production in 501 muscles of Achondroplasia. The main finding is that Achondroplasia produce 23% 502 less specific force than controls. These results may only explain the variance in 503 muscle morphology as further work into methodological, and myofilament 504 differences within Achondroplasic specific force is needed to increase the validity of 505 these data. 
